Equateq in the Press
EQUATEQ'S OFFERINGS
EQUATEQ NEWS
Equateq and Dignity Sciences announce IP and Supply Deal
Equateq and Dignity Sciences announced a two-tier strategic deal comprising a supply agreement, and the assignment of IP covering the use of synthetic lipids for the topical treatment of hyper-proliferative skin conditions.
EQUATEQ AND DIGNITY SCIENCES ANNOUNCE IP AND SUPPLY DEAL: JAN. 11, 2012
Equateq and Dignity Sciences Ltd today announced a two-tier strategic deal comprising a supply agreement, and the assignment of IP covering the use of synthetic lipids for the topical treatment of hyper-proliferative skin conditions.
Under the venture, Equateq will assign to Dignity its patent application PCT/GB2010/000844 (WO2010125340), enabling the prosecution of claims that would cover topical formulations of Dignity Sciences’ lead compound, DS107, and the company’s highly potent second generation compounds. Equateq generated the patent based on pre-clinical work showing strong anti-inflammatory mechanisms in the use of particular lipids, indicating potential for treatment of various topical skin conditions, such as dermatitis and eczema. Equateq will also be the exclusive supplier of Dignity’s specific lipids, which will be manufactured at its cGMP API plant located in the Western Isles of Scotland. Exact terms of both agreements have not been disclosed.
Adam Kelliher, Equateq CEO and founder, said: “Dignity understands the vast potential of these novel compounds, which hold great promise for providing effective treatment for chronic skin conditions, with no side effects. We look forward to supporting their plans to prove robust clinical efficacy, and ultimately, bringing these APIs to market.”
Jonathan D. Rowe, Ph.D., Head of Intellectual Property and Portfolio Strategy for Dignity Sciences, stated, "The development and acquisition of intellectual property is a cornerstone of Dignity’s product development model. This is an ideal agreement, allowing each company to focus on its strengths. Dignity Sciences has the expertise to bring these compounds to market, and Equateq has the know-how and capability to best manufacture the active ingredients."
About Equateq Equateq is a privately-owned lipid production company based in the Western Isles of Scotland, where its facility has been concentrating lipids for nearly 30 years. Equateq is fully cGMP compliant, as certified by the UK's health authority, the MHRA, and for manufacturing lipid APIs, uses its Maxomega™ technology. This concentration method is based on advanced HPLC separation, and allows Equateq to deliver specific lipid APIs at up to 99% purity at commercial scale.
About DS107 DS107 is a topical formulation of a semi-synthetic omega-6 fatty acid. DS107 is currently being studied for use in treating acne and atopic dermatitis
About Dignity Sciences
Dignity Sciences, a privately held biopharmaceutical company, was established to discover and develop scientifically innovative healthcare solutions that improve the quality of life for people with diseases caused by the ageing process. Dignity Sciences is led by recognized experts in developing omega-6 and omega-3 fatty acids, including their bioactive derivatives, for the treatment of human disease.
Ends.
For further enquiries, please contact: Rachel Stojevic: rachel@equateq.com
Equateq Ltd - A Global Leader with Local Impact: Nov. 18, 2011
The Secretary of State for Scotland, Michael Moore, visited the Equateq facility on the Isle of Lewis, where he was briefed on the company's plans to greatly expand its production and increase its workforce to meet surging demand pharmaceutical lipid concentrates, the company said today.
Scotland's life sciences sector consists of 620 business and organizations, with more than 31,000 employees across all the main life sciences areas. This sector contributes around £3bn pa to the Scottish economy, and is a main focus for the Scottish government.
Equateq Ltd - A Global Leader with Local Impact: Nov. 18, 2011
The Secretary of State for Scotland, Michael Moore, visited the Equateq facility on the Isle of Lewis, where he was briefed on the company's plans to greatly expand its production and increase its workforce to meet surging demand pharmaceutical lipid concentrates, the company said today.
Read more: Official Press Relase
Equateq-Amarin Supply Deal Signed: May.31,2011
Equateq today announced it has signed a long-term supply agreement with Amarin under which the lipid specialist will, on commercialisation, sell up to $20m per annum of API for use in AMR101.
Read more: Official Press Relase
Maxomega Oils in Japan A Step Closer - Jan. 24, 2011
Pharmaceutical Lipid Manufacturer Equateq has secured a manufacturer’s accreditation for Japan, taking the company a step closer to offering its Maxomega™ super-pure omega oil concentrates in the world’s second largest pharmaceutical market.
Read More: Official Press Release
Maxomega-90: A 'Blank Canvas' for Omega Oil Formulators - May. 7, 2010
High end Nutraceutical companies can now provide their customers with almost any ratio of EPA and DHA omega oil concentrates they want, with the launch of Maxomega-90, a range that exploits pharmaceutical sector separation methods to deliver omega-3 EPA and DHA in any 90% combination.
Omega Actives for Active People: Equateq launches Whey-O3 - Dec. 5, 2009
The dual-benefits of Whey-protein and concentrated Omega-3 fish oils can now be enjoyed in a unique combination product with the launch of Whey-O3 today.
Read more: http://www.nutraingredients.com/Industry/Scots-debut-whey-omega-3-blend
Pure, Potent and Natural Omega Oils: Equateq's Crystalpure™ Range Launched - Apr. 22, 2009
Customers in the omega oils sector can now use concentrates that are truly natural and bioavailable, with the launch of Equateq's Crystalpure™ Range.
Read more: http://www.nutraingredients.com
Equateq bullish about lipid API Market - Aug. 27, 2008
Equateq CEO Adam Kelliher is interviewed about the state of the lipid API Market for Pharmatechnologist Magazine
Read more:? http://www.in-pharmatechnologist.com/
Equateq Facility Certified for GMP Pharma Production - Aug. 22, 2008
The fatty acid concentration plant run by Equateq in the Western Isles of Scotland has been certified as GMP compliant by Britain’s healthcare authority, giving it the necessary credentials to produce high-end lipid compounds as active pharmaceutical ingredients for the booming omega oils sector, the company announced Friday.
Read more: http://www.whatsnewinpharma.com/
Equateq opens super omega-3 factory in Scotland - Aug 25, 2007
A production and research facility able to make super-pure fatty acid concentrates for the nutrition industry has officially opened in the Western Isles of Scotland with the potential to offer gold standard omega-3.
Read more: nutraingredients.com
Pioneer's daughter to reopen Isles factory - Aug. 23, 2007
A FACTORY on Lewis set up by the medical pioneer David Horrobin will be reopened this week by his daughter.
Read more: scotsman.com
The final frontier for fatty acids - Aug. 20, 2007
A new facility has opened in the Western Isles of Scotland boasting a unique two-stage process for making fatty acid concentrates of up to 99% purity from marine or botanical oils.
Read more: foodingredientsinfo.com